These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7308274)

  • 21. Double-blind crossover comparison of Tegretol-XR and Tegretol in patients with epilepsy. The Tegretol OROS Osmotic Release Delivery System Study Group.
    Neurology; 1995 Sep; 45(9):1703-7. PubMed ID: 7675230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conventional vs controlled-release carbamazepine: a multicentre, double-blind, cross-over study.
    Canger R; Altamura AC; Belvedere O; Monaco F; Monza GC; Muscas GC; Mutani R; Panetta B; Pisani F; Zaccara G
    Acta Neurol Scand; 1990 Jul; 82(1):9-13. PubMed ID: 2239143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative bioavailability and steady state fluctuations of Tegretol commercial and carbamazepine OROS tablets in adult and pediatric epileptic patients.
    Thakker KM; Mangat S; Garnett WR; Levy RH; Kochak GM
    Biopharm Drug Dispos; 1992 Nov; 13(8):559-69. PubMed ID: 1421050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and cognitive effects of carbamazepine formulations with different dissolution rates.
    Aldenkamp AP; Rentmeester T; Hulsman J; Majoie M; Doelman J; Diepman L; Schellekens A; Franken M; Olling M
    Eur J Clin Pharmacol; 1998 Apr; 54(2):185-92. PubMed ID: 9626926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carbamazepine and carbamazepine-10,11- epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects.
    Kuhnz W; Jäger-Roman E; Rating D; Deichl A; Kunze J; Helge H; Nau H
    Pediatr Pharmacol (New York); 1983; 3(3-4):199-208. PubMed ID: 6677873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The epoxide of carbamazepine.
    McKauge L; Tyrer JH; Eadie MJ
    Clin Exp Neurol; 1979; 16():95-104. PubMed ID: 550961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.
    Bertilsson L; Tomson T
    Clin Pharmacokinet; 1986; 11(3):177-98. PubMed ID: 3524954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjustment of carbamazepine dose to offset the effects of the interaction with remacemide hydrochloride in a double-blind, multicentre, add-on drug trial (CR2237) in refractory epilepsy.
    Mawer GE; Jamieson V; Lucas SB; Wild JM
    Epilepsia; 1999 Feb; 40(2):190-6. PubMed ID: 9952266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva.
    Westenberg HG; van der Kleijn E; Oei TT; de Zeeuw RA
    Clin Pharmacol Ther; 1978 Mar; 23(3):320-8. PubMed ID: 627139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carbamazepine in trigeminal neuralgia: clinical effects in relation to plasma-concentration.
    Tomson T; Tybring G; Bertilsson L; Ekbom K; Rane A
    Ups J Med Sci Suppl; 1980; 31():45-6. PubMed ID: 6935859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carbamazepine metabolism in man. Induction and pharmacogenetic aspects.
    Eichelbaum M; Tomson T; Tybring G; Bertilsson L
    Clin Pharmacokinet; 1985; 10(1):80-90. PubMed ID: 3971637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients.
    MacKichan JJ; Duffner PK; Cohen ME
    Br J Clin Pharmacol; 1981 Jul; 12(1):31-7. PubMed ID: 7248139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative bioavailability of four Carbamazepine tablet formulations available in the Kenyan market.
    Oluka MO; Mitema ES; Kibwage IO; Kwasa TO; Kokwaro GO
    East Afr Med J; 1996 May; 73(5):323-6. PubMed ID: 8756037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of dosage frequency of carbamazepine on drug serum levels in epileptic patients.
    Ghose K; Fry DE; Christfides JA
    Eur J Clin Pharmacol; 1983; 24(3):375-81. PubMed ID: 6861851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Individual and combined antiepileptic and neurotoxic activity of carbamazepine and carbamazepine-10,11-epoxide in mice.
    Bourgeois BF; Wad N
    J Pharmacol Exp Ther; 1984 Nov; 231(2):411-5. PubMed ID: 6491988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide.
    Tomson T; Tybring G; Bertilsson L
    Clin Pharmacol Ther; 1983 Jan; 33(1):58-65. PubMed ID: 6848300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dissolution and relative bioavailability of two carbamazepine preparations for children with epilepsy.
    Hartley R; Aleksandrowicz J; Bowmer CJ; Cawood A; Forsythe WI
    J Pharm Pharmacol; 1991 Feb; 43(2):117-9. PubMed ID: 1672895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioavailability of four different pharmaceutical preparations of carbamazepine.
    Pynnönen S; Mäntylä R; Iisalo E
    Acta Pharmacol Toxicol (Copenh); 1978 Oct; 43(4):306-10. PubMed ID: 362821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine.
    Bialer M; Yacobi A; Moros D; Levitt B; Houle JM; Munsaka MS
    Epilepsia; 1998 May; 39(5):513-9. PubMed ID: 9596204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diurnal variation of carbamazepine and carbamazepine-10,11-epoxide in plasma and saliva in children with epilepsy: a comparison between conventional and slow-release formulations.
    Eeg-Olofsson O; Nilsson HL; Tonnby B; Arvidsson J; Grahn PA; Gylje H; Larsson C; Norén L
    J Child Neurol; 1990 Apr; 5(2):159-65. PubMed ID: 2111837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.